Xue Han

ORCID: 0009-0001-5812-9363 · 6 papers in corpus
lab-animal 2025
Advanced science (Weinheim, Baden-Wurttemberg, Germany) ·doi:10.1002/advs.202503192

Atherosclerosis has an urgent need for new therapeutic targets. Protein kinases orchestrate multiple cellular events in atherosclerosis and may provide new therapeutic targets for atherosclerosis. Here, a protein kinase, WEE1 G2 checkpoint …

meta-analysis 2024
EClinicalMedicine ·doi:10.1016/j.eclinm.2024.102897

BACKGROUND: Embryonic ploidy is critical for the success of embryo transfer. Currently, preimplantation genetic testing for aneuploidy (PGT-A) is the gold standard for detecting ploidy abnormalities. However, PGT-A has several inherent limi…

lab-animal 2023
Apoptosis : an international journal on programmed cell death ·doi:10.1007/s10495-023-01845-1

Cuproptosis is a new form of programmed cell death, which is associated with the mitochondrial TCA (tricarboxylic acid) cycle. But the functions of cuproptosis in endometriosis progression are still unknown. Here, we find that cuproptosis s…

meta-analysis 2021
Gynecologic and obstetric investigation ·doi:10.1159/000516517

INTRODUCTION: This study aimed to evaluate whether endometriosis could disturb the mental health and health-related quality of life (HRQoL) of patients and to provide a new prospective for further treatment of endometriosis. METHODS: A com…

2020
·doi:10.12998/wjccc.v8.i23.6198
case-report 2020
World journal of clinical cases ·doi:10.12998/wjcc.v8.i23.6206

BACKGROUND: Massive hemorrhagic ascites caused by endometriosis is exceedingly rare, and the treatment strategy remains controversial. Here, we report a case of endometriosis with massive hemorrhagic ascites treated with a novel triple ther…